ST’s Tankyrase Inhibitor Moves Ahead With Govt Support
This article was originally published in PharmAsia News
South Korea’s ST Pharm is set to benefit from a government R&D support program for the development of a tankyrase inhibitor to treat KRAS mutant colorectal cancer. Through rapid preclinical testing, the affiliate of Dong-A Socio Holdings hopes to receive IND approval from the US FDA by the end of next year to begin clinical trials in the US.
Register for our free email digests: